Measuring Type 2 inflammation in asthma with a breath test in everyday care
Uses a breath test to measure airway inflammation in adults with asthma.
Plain-language title generated from the registry record
Registry title: Quantifying the Burden of Type 2 (T2) Inflammation in Asthma
Key facts
- Where
- New York, United StatesSee the site
Where in United States
- Mount Sinai Health SystemNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Trial code
- NCT07675044
- Record updated
- 30 June 2026
- Original description
This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.Read full original descriptionShow less
QUANTAS-PC: Quantifying the Burden of Type 2 (T2) Inflammation in Asthma in Primary Care and Community Specialty Practices
This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.
Participant Inclusion Criteria; Age 18 years and older; Ability to consent and comply with protocol assessments; Pre-existing diagnosis of asthma and has started treatment; Participant Exclusion Criteria; Participant deemed medically ineligible per the opinion of the investigator; History of respiratory/lung disease other than asthma (e.g., COPD, emphysema, chronic bronchitis, tuberculosis, cystic fibrosis, lung cancer, recurrent pneumonia or other chronic lung disease); Participants who meet criteria for GINA 5, severe asthma (ICS + additional controllers); Current Enrollment in an asthma intervention trial that could affect asthma outcomes clinically and T2 biomarkers; Visit with a specialist (i.e. Pulmonologist or Allergist) in the past year who is measuring FeNO levels.